Get the Stockscreener App
1.705
48.32%
0.515
After Hours:
1.53
-0.175
-10.26%
Artelo Biosciences Inc stock is traded at $1.705, with a volume of 23.66M.
It is up +48.32% in the last 24 hours and down -56.26% over the past month.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
See More
Previous Close:
$1.19
Open:
$1.91
24h Volume:
23.66M
Relative Volume:
6.14
Market Cap:
$3.98M
Revenue:
-
Net Income/Loss:
$-12.88M
P/E Ratio:
-0.0478
EPS:
-35.6417
Net Cash Flow:
$-8.79M
1W Performance:
+29.78%
1M Performance:
-56.26%
6M Performance:
-64.56%
1Y Performance:
-89.71%
1-Day Range:
$1.62
$1.91
1-Week Range:
$1.19
$1.91
52-Week Range:
$1.19
$85.80
Artelo Biosciences Inc Stock (ARTL) Company Profile
Name
Artelo Biosciences Inc
Sector
Industry
Phone
858-925-7049
Address
505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA
Compare ARTL vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARTL
Artelo Biosciences Inc
|
1.705 | 2.78M | 0 | -12.88M | -8.79M | -35.64 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Artelo Biosciences Inc Stock (ARTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-08-25 | Upgrade | D. Boral Capital | Hold → Buy |
| Feb-12-21 | Initiated | Ladenburg Thalmann | Buy |
Artelo Biosciences Inc Stock (ARTL) Latest News
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
ARTL Stock In Focus As Artelo Biosciences Taps AI For Drug Pipeline - StocksToTrade
Artelo Biosciences ARTL Jumps On AI Drug Discovery Pact - timothysykes.com
Which stocks are moving before the opening bell on Tuesday? - ChartMill
Wondering what's happening in today's after-hours session? - ChartMill
Why did ARTL stock skyrocket over 141% pre-market today? - MSN
Trending Stocks Today | Artelo Biosciences Soars 69.19% Post-Market - Moomoo
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Get insights into the top gainers and losers of Friday's after-hours session. - ChartMill
ARTL Stock Chart | ARTELO BIOSCIENCES INC (NASDAQ:ARTL) - ChartMill
[EFFECT] ARTELO BIOSCIENCES, INC. SEC Filing - Stock Titan
ARTL Stock Price, Quote & Chart | ARTELO BIOSCIENCES INC (NASDAQ:ARTL) - ChartMill
Avis Budget Group, Toyota Motor and other big stocks moving lower in Monday's pre-market session - MSN
Why LiveRamp Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket - Sahm
ARTL (NASDAQ: ARTL) terminates $6.5M ATM; sold 50,858 shares for $451.5K - Stock Titan
Trending Industry Today: Artelo Biosciences Leads Losses In SOL Reserve Concept Stocks - Moomoo
Artelo Biosciences to terminate at-the-market offering agreement effective May 18, 2026SEC filing - marketscreener.com
Artelo Biosciences Ends ATM Offering, Shifts Financing Strategy - The Globe and Mail
Artelo Biosciences (NASDAQ: ARTL) ends $6.5M at-the-market stock program - Stock Titan
Artelo Biosciences | SCHEDULE 13G: Others - Moomoo
Armistice Capital (ARTL) reports 235,823 shares, 9.99% stake - Stock Titan
Artelo Biosciences (NASDAQ: ARTL) widens Q1 loss but boosts liquidity - Stock Titan
Artelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial Results - Yahoo Finance
Artelo Biosciences (ARTL) amends S-3; Exhibit 4.3 filed, fees noted - Stock Titan
Artelo Biosciences Stock Soars On Strong Preclinical Data In Par With Zoloft For Experimental Depression Drug - MSN
TradingKey - TradingKey
Artelo Biosciences Stock Soars 114% After Promising Depression Treatment Data - MSN
Why is ARTL stock soaring pre-market today? - MSN
Artelo Biosciences | S-3: Registration statement for specified transactions by certain issuers - Moomoo
Artelo Biosciences may offer securities up to $75 millionSEC filing - marketscreener.com
Artelo Biosciences (NASDAQ: ARTL) files $75M shelf, includes $69.29M unsold - Stock Titan
What's behind the rise in Artelo Biosciences stock? - MSN
Artelo Biosciences (ARTL) Partners with ScienceMachine for AI-Dr - GuruFocus
Artelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 Inhibitor Development - The Manila Times
Artelo Biosciences Announces Strategic Collaboration with Artificial Intelligence Leader Sciencemachine Highlighting New Expansion Opportunities and Insights for FABP5 Inhibitor Development - marketscreener.com
ARTL - Finviz
Artelo Biosciences stock soars after withdrawing SEC filing - MSN
Artelo (ARTL) Stock Fundamentals | Q4 2025: EPS Exceeds ExpectationsRetail Trader Ideas - Cổng thông tin điện tử tỉnh Tây Ninh
Artelo Biosciences Inc Stock (ARTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.49%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):